A Nanoliposomal Adjuvant Containing Cobalt-Porphyrin Phospholipids For Anthrax Protective Antigen
MetadataShow full item record
The application of only FDA-licensed human anthrax vaccine BioThrax is limited due to it requires five-immunization series over 18 months to induce protective immune response and annually booster to maintain immunity; In addition, the employment of trace LF and EF in the formulation rises concerns on side effects. In this study, we aim to develop an anthrax vaccine with liposomes containing cobalt-porphyrin-phospholipids (CoPoP) as adjuvant and anthrax protective antigen (PA) with his-tags as antigen that can provide long-term protective immunity rapidly with less immunization series and injection dose. His-tagged PA is able to bind to liposomes containing CoPoP spontaneously to form antigen-adjuvant nanoparticle with size around 150 nm. Mice immunization of PA conjugated with liposomes containing CoPoP and PHAD with immunization regimens (single immunization, and shortened prime-boost immunization intervals) induced high PA-neutralized IgG antibodies in 21 days and provided complete immune protection to mice against anthrax spore and lethal toxin challenge.